stockrow
Friday 6 November 2026
Export KOD’s income statement to Excel — free account
Kodiak Sciences Inc.
- EPS
- −1.94%
- Free cash flow
- −33.9%
Quarter to June 2026, against a year earlier
98.85
7.83
+8.60%
Follow KOD
Alert me
Kodiak Sciences Inc. (KOD) Operating cash flow
Kodiak Sciences Inc.'s operating cash flow for fiscal 2025 was −$136.0M, compared with −$117.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$158.5M. Over the past ten years it has ranged from −$206.5M (fiscal 2022) to −$16.0M (fiscal 2016); the current reading is higher than 40% of that period. Kodiak Sciences Inc. ranks 516th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$136.0M | — |
| FY2024 | −$117.3M | — |
| FY2023 | −$154.2M | — |
| FY2022 | −$206.5M | — |
| FY2021 | −$182.3M | — |
| FY2020 | −$83.4M | — |
| FY2019 | −$39.1M | — |
| FY2018 | −$29.0M | — |
| FY2017 | −$17.7M | — |
| FY2016 | −$16.0M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$46.2M | — |
| Mar 2026 | −$40.0M | — |
| Dec 2025 | −$39.4M | — |
| Sep 2025 | −$32.9M | — |
| 33 more quarters | Free account |
Against its own ten years
Low −$206.5M
High −$16.0M
Ten-year median
−$100.4M
Current reading's percentile
40
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $91.0M |
| PTCT PTC Therapeutics, Inc. compare | $10.5M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.2M |
| ORKA Oruka Therapeutics, Inc. compare | −$100.9M |
| KOD Kodiak Sciences Inc. | −$158.5M |
| CGON CG Oncology, Inc. compare | −$178.5M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$271.3M |
| IMVT Immunovant, Inc. compare | −$414.3M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$496.4M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item